This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
GoHealth Crescita futura
Criteri Future verificati 2/6
Si prevede che GoHealth aumenterà gli utili e i ricavi rispettivamente del 87% e 41.7% all'anno, mentre si prevede che l'EPS crescerà del 100.5% all'anno.
Informazioni chiave
87.0%
Tasso di crescita degli utili
100.46%
Tasso di crescita dell'EPS
| Insurance crescita degli utili | 1.5% |
| Tasso di crescita dei ricavi | 41.7% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 16 Jul 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento narrativa • Jul 17
GOCO.Q: Chapter 11 Restructuring Will Drive Future Upside After Nasdaq Delisting
Analysts have reduced their fair value estimate for GoHealth from $5.13 to $2.75 per share, citing updated assumptions around revenue growth, profitability, and a lower projected future P/E multiple. What’s in the News for GoHealth GoHealth and several affiliates filed voluntary petitions for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 7, 2026, with reported assets in the range of US$500 million to US$1b and liabilities in the range of US$1b to US$10b (Bankruptcy Filing).Aggiornamento narrativa • Jun 15
GOCO: Chapter 11 Reorganization Will Drive Future Upside Despite Imminent Delisting
Analysts have trimmed their price targets on GoHealth, citing slightly softer revenue growth assumptions and revised P/E outlooks following a recent downgrade highlighted in Street research. What's in the News GoHealth and certain subsidiaries filed voluntary Chapter 11 petitions in the US Bankruptcy Court for the District of Delaware on June 7, 2026, seeking reorganization with listed assets of $500 million to $1 billion and liabilities of $1 billion to $10 billion, according to court filings.Aggiornamento narrativa • Jun 01
GOCO: Higher Growth Assumptions Will Support Upside Despite Nasdaq Listing Risk
Analysts have adjusted their price target on GoHealth from $4.70 to $5.13, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E following recent research, including a downgrade at Freedom Broker. What's in the News GoHealth reported that it will be unable to file its next 10-Q with the SEC by the required deadline, citing a delayed SEC filing as of May 18, 2026.
Aggiornamento narrativa • Apr 30
GOCO: Lower P E And Improved Revenue Outlook Will Support Returns
Analysts have cut their 12 month price target for GoHealth by about $3, reflecting a reset in fair value assumptions along with updated views on revenue growth, margins and future P/E, following a recent downgrade highlighted in Street research. Analyst Commentary Bearish analysts are framing the latest downgrade as part of a broader reset in expectations for GoHealth, with the lower 12 month price target seen as a response to questions about how quickly the business can translate its model into consistent, scalable earnings.Aggiornamento narrativa • Apr 14
GOCO: Lower Earnings Multiple Will Support Upside Despite Nasdaq Compliance Risk
Analysts cut their GoHealth price target from $7.70 to $4.70 as they factor in updated assumptions for revenue growth and margins, and incorporate the recent downgrade at Freedom Broker into their outlook. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$4.70 target as a cleaner entry point that better reflects current expectations for revenue growth and margins, which they see as more achievable under updated assumptions.Aggiornamento narrativa • Mar 31
GOCO: Discount Rate Tweaks Will Support Upside Despite Nasdaq Compliance Risk
Analysts have nudged up their price target on GoHealth to $7.70, citing a slightly lower discount rate and modest tweaks to long term revenue growth, profit margin, and future P/E assumptions as key drivers of the change. What's in the News On March 18, 2026, GoHealth received a notice from Nasdaq that it is not in compliance with the minimum US$35 million market value of listed securities requirement under Listing Rule 5550(b)(2) (Nasdaq filing).Aggiornamento narrativa • Mar 17
GOCO: Stable Assumptions And Low Future P E Will Support Returns
Analysts have kept their GoHealth price target unchanged at $4.50. They point to only slight tweaks in revenue growth, profit margin and forward P/E assumptions that do not materially alter their overall view of the stock.Aggiornamento narrativa • Mar 03
GOCO: Stronger Margins And Lower P E Will Support Future Cash Flow
Analysts have trimmed their price target on GoHealth to reflect slightly weaker revenue expectations, a modestly stronger profit margin, and a marginally lower forward P/E. This results in a small downward adjustment in their $ price outlook for the stock.Aggiornamento narrativa • Feb 17
GOCO: Carrier Relationship Reset Will Support Future Cash Flow Recovery
Analysts have sharply reduced GoHealth's target, with one firm lowering its price target to $5 from $12 after Q3 results came in below expectations because of topline weakness tied to a suspended relationship with a large carrier. Analyst Commentary Bearish analysts are recalibrating their expectations after Q3 results came in well below what they were looking for, and the cut in the price target to $5 from $12 signals a more cautious stance on the stock.Aggiornamento narrativa • Feb 03
GOCO: Cash Burn Discipline And Carrier Reset Could Support Future Upside
Analysts have cut their price targets on GoHealth, including a reduction to US$5 from US$12. They cited weaker than expected Q3 results tied to topline softness from a suspended carrier relationship, a pullback in new enrollment growth, and ongoing concerns about market headwinds and cash flow sustainability.Aggiornamento narrativa • Jan 20
GOCO: Cash Discipline And Carrier Reset Will Support Future Cash Flow
Analysts have sharply reduced their GoHealth price targets, with one moving from US$12 to US$5. This reflects weaker Q3 results tied to a suspended carrier relationship, as well as concerns about ongoing market headwinds and cash flow visibility.Aggiornamento narrativa • Jan 06
GOCO: Focus On Cash Burn Discipline And Carrier Reset Supporting Future Stability
Narrative Update on GoHealth Analysts have cut their 12 month price target for GoHealth to US$5.00 from US$12.00, reflecting weaker Q3 results tied to a suspended relationship with a large carrier, softer revenue and Medicare submissions, a pullback in new enrollment growth, and concerns around ongoing market headwinds and uncertainty about achieving sustainable positive cash flow. Analyst Commentary Recent research updates on GoHealth reflect a cautious reset of expectations following Q3 results that came in below prior estimates, with price targets and ratings adjusted to reflect execution risks and a more uncertain growth outlook.Aggiornamento narrativa • Dec 15
GOCO: Cash Flow Improvements Will Outweigh Carrier Loss And Enrollment Pullback
Analysts have sharply reduced their price target on GoHealth from approximately $12.00 to about $5.00 per share. This reflects weaker than expected Q3 results, revenue headwinds from a suspended carrier relationship, and persistent concerns about the company's ability to deliver sustainable growth and cash flow in a challenging market.Aggiornamento narrativa • Dec 01
GOCO: Focus On Profitability And Cash Burn Reduction Will Drive Future Stability
Analysts have sharply reduced GoHealth's fair value estimate from $14 to $7.70 per share. They cite ongoing market headwinds, weaker-than-expected Q3 results, and challenges in revenue growth as key reasons for the downward revision.Aggiornamento narrativa • Nov 17
GOCO: Recent Credit Move Will Boost Flexibility Ahead of Enrollment Period
Analysts have revised GoHealth's fair value estimate downward from $17.20 to $14.00. This change is due to updated model assumptions and increased caution surrounding revenue growth following recent company results and financial transactions.Aggiornamento narrativa • Aug 25
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
GoHealth’s price target has been revised downward to $18.40, primarily reflecting reduced expectations for both future earnings multiples and revenue growth. What's in the News GoHealth has formed a Transformation Committee with new board members to evaluate strategic opportunities, including acquisitions, securitizations, and capital structure options.Aggiornamento narrativa • Aug 10
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
Despite higher revenue growth forecasts, GoHealth’s future P/E multiple has dropped sharply, indicating reduced investor confidence in earnings quality or sustainability, leading to a lower consensus price target of $19.60. What's in the News GoHealth has formed a Transformation Committee to evaluate acquisitions, financial structure options, securitizations, and other strategic opportunities for value creation.
Nuova narrativa • Mar 31
Medicare Engagement And Efficiency Will Drive Future Savings
GoHealth's shift to Medicare engagement enhances consumer relations and boosts operational efficiency, lowering costs and improving margins.Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 548 | -23 | N/A | N/A | 1 |
| 12/31/2027 | 397 | -65 | -21 | -7 | 3 |
| 12/31/2026 | 261 | -95 | -16 | -6 | 1 |
| 3/31/2026 | 153 | -294 | -108 | -103 | N/A |
| 12/31/2025 | 362 | -261 | -130 | -122 | N/A |
| 9/30/2025 | 738 | -203 | -79 | -68 | N/A |
| 6/30/2025 | 822 | -30 | -60 | -48 | N/A |
| 3/31/2025 | 834 | -2 | -59 | -47 | N/A |
| 12/31/2024 | 799 | -7 | -35 | -22 | N/A |
| 9/30/2024 | 686 | -33 | 18 | 35 | N/A |
| 6/30/2024 | 700 | -64 | 37 | 54 | N/A |
| 3/31/2024 | 737 | -67 | 85 | 101 | N/A |
| 12/31/2023 | 735 | -67 | 95 | 109 | N/A |
| 9/30/2023 | 527 | -127 | -13 | -3 | N/A |
| 6/30/2023 | 528 | -132 | 77 | 86 | N/A |
| 3/31/2023 | 544 | -146 | 17 | 27 | N/A |
| 12/31/2022 | 632 | -150 | 47 | 61 | N/A |
| 9/30/2022 | 1,012 | -242 | -137 | -125 | N/A |
| 6/30/2022 | 1,091 | -233 | -282 | -260 | N/A |
| 3/31/2022 | 1,129 | -201 | -298 | -276 | N/A |
| 12/31/2021 | 1,062 | -189 | -319 | -299 | N/A |
| 9/30/2021 | 1,059 | 2 | -237 | -215 | N/A |
| 6/30/2021 | 1,010 | -33 | -157 | -142 | N/A |
| 3/31/2021 | 941 | -20 | -121 | -107 | N/A |
| 12/31/2020 | 877 | -19 | -129 | -114 | N/A |
| 9/30/2020 | 720 | -27 | -10 | 3 | N/A |
| 6/30/2020 | 664 | 16 | -28 | -17 | N/A |
| 3/31/2020 | 611 | 10 | 13 | 22 | N/A |
| 12/31/2019 | 540 | 16 | N/A | 0 | N/A |
| 12/31/2018 | 226 | 28 | N/A | 5 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che GOCO.Q rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che GOCO.Q rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che GOCO.Q rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di GOCO.Q ( 41.7% all'anno) crescerà più rapidamente del mercato US ( 13.5% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di GOCO.Q ( 41.7% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di GOCO.Q è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/21 20:50 |
| Prezzo dell'azione a fine giornata | 2026/07/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
GoHealth, Inc. è coperta da 13 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Steven Valiquette | Barclays |
| Michael Cherny | BofA Global Research |
| Elizabeth Anderson | Evercore ISI |